Silexion Therapeutics Corp. (SLXN) Doses First Patient in Phase 2/3 SIL204 Trial

Silexion Therapeutics Corp. dosed the first patient in its multinational Phase 2/3 trial of SIL204 plus chemotherapy in locally advanced pancreatic cancer, starting at Tel Aviv Sourasky Medical Center, with expansion sites planned in Israel and Germany.Material DetailsContext by AI AnalystThis is a…